Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3500
-0.0020 (-0.57%)
Official Closing Price
Updated: 8:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cybin Inc
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
GAINERS: Mind Medicine (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
GAINERS: Field Trip Health (NASDAQ:
Via
Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
January 23, 2022
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
GAINERS: GH Research (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
January 19, 2022
GAINERS: Revive Therapeutics (OTC:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
GAINERS: Cybin (AMEX:
Via
Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
January 18, 2022
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:
Via
Benzinga
Cybin Notes 'Milestone' Step with USPTO Notice of Allowance for CYB004
January 12, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi...
Via
Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
January 11, 2022
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines.
Via
Benzinga
Cybin CEO Participation in Upcoming Events Recognizes Company Expertise
January 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi...
Via
Benzinga
Why Cybin Shares Are Rising
January 11, 2022
Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel...
Via
Benzinga
Cybin Highlights Adelia's Milestone Achievement
January 10, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cybin (NYSE: CYBN), a biotechnology...
Via
Benzinga
Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High
January 09, 2022
There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents.
Via
Talk Markets
Cybin Witnessing Advancement in R&D Pipeline
December 29, 2021
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating...
Via
Benzinga
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
December 24, 2021
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?
Via
Talk Markets
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
December 17, 2021
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.
Via
Talk Markets
Cybin Receives Notice of Allowance from U.S. Patent Office
December 15, 2021
Cybin (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (...
Via
Benzinga
Cybin Developing Safer, More Effective Psilocybin Therapies
December 14, 2021
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a...
Via
Benzinga
Cybin to Fund, Support Psychedelic Clinic at Manhattan Hospital
December 10, 2021
Company receives grant to fund clinic for marginalized, underserved NYC communities New clini...
Via
Benzinga
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...
Via
Benzinga
Topics
Derivatives
Exposures
Derivatives
Cybin Touts Highlights of 'Transformative' Second-Quarter Performance
December 02, 2021
The report notes significant and swift advancements in the company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment...
Via
Benzinga
Cybin Announces FDA Approvals, Participation in Conference
December 01, 2021
Cybin (NYSE:
Via
Benzinga
Exposures
Product Safety
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
November 30, 2021
Cybin (NYSE:CYBN), a biotech company focused on progressing ...
Via
Benzinga
Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress
November 30, 2021
The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for...
Via
Benzinga
Exposures
Product Safety
Cybin Supports Psychedelic Treatment Clinic Through Grant
November 23, 2021
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first...
Via
Benzinga
NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved
November 23, 2021
Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE:
Via
Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
November 21, 2021
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.
Via
Talk Markets
Cybin 'One Step Closer' to Creating Best Therapy for Mental Health
November 19, 2021
Company releases positive results from a pre-clinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.